New Molecules and Strategies in the Field of Anticancer Agents

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 17, 14 Issues, 2017

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand
Université Clermont Auvergne

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

New Molecules and Strategies in the Field of Anticancer Agents

Anti-Cancer Agents in Medicinal Chemistry, 4(3): 247-262.

Author(s): Marchini S., D'Incalci M. and Broggini M.

Affiliation: Dep. of Oncology, “MarioNegri” Institute for Pharmacological Research, Milan Italy, Via Eritrea N62, 20154 Milan Italy


The conventional chemotherapy is mostly based on the evidence that proliferating cells are more sensitive to anticancer agents than non-dividing cells. This is the main reason why these compounds are not tumour specific and their selectivity is generally in favour of rapidly growing cells (haematopoietic or intestine. i.e.) rather than discriminating against any fundamental biological difference between normal and tumour cells. The critical issue is at present to identify how tumour cells differ from normal cells and how those differences can be exploited therapeutically for designing and synthesising new drugs with a selective mechanism of action and thus with an improved therapeutic index. This topic and the strategies to identify these new targets will be discussed in details in the review. The expanding knowledge on molecular biology of cancer cells has allowed in the last years the identification of different molecular pathways altered in cancer that could be exploited as potential therapeutic targets. For most of the pathways previously disclosed it has been a problem to develop selective molecules with a relevant clinic impact. To target those specific genetics defects, different kind of molecules (antibodies, “antisense oligonucleotides”, short peptides and small molecules) have been made and some of them are currently under investigation. This review will be focused mainly on three different classes of compounds: I. Compounds designed to hit or inhibit crucial molecular targets. II. Novel DNA minor groove binders. III. Products of marine origin that exhibit novel mode of action.


new anticancer drugs, cancer chemotherapy target oriented drugs, minor groove binders, dna interacting agents.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 4
Issue Number: 3
First Page: 247
Last Page: 262
Page Count: 16
DOI: 10.2174/1568011043352966
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science